Abstract:In recent years, clustered regularly interspaced short palindromic repeats (CRISPRs) and CRISPR-associated (Cas) protein have emerged as a revolutionary gene editing tool to treat inherited disorders affecting different organ systems, such as blood and muscles. Both hematological and neuromuscular genetic disorders benefit from genome editing approaches but face different challenges in their clinical translation. The ability of CRISPR/Cas9 technologies to modify hematopoietic stem cells ex vivo has greatly accelerated the development of genetic therapies for blood disorders. In the last decade, many clinical trials were initiated and are now delivering encouraging results. The recent FDA approval of Casgevy, the first CRISPR/Cas9-based drug for severe sickle cell disease and transfusion-dependent β-thalassemia, represents a significant milestone in the field and highlights the great potential of this technology. Similar preclinical efforts are currently expanding CRISPR therapies to other hematologic disorders such as primary immunodeficiencies. In the neuromuscular field, the versatility of CRISPR/Cas9 has been instrumental for the generation of new cellular and animal models of Duchenne muscular dystrophy (DMD), offering innovative platforms to speed up preclinical development of therapeutic solutions. Several corrective interventions have been proposed to genetically restore dystrophin production using the CRISPR toolbox and have demonstrated promising results in different DMD animal models. Although these advances represent a significant step forward to the clinical translation of CRISPR/Cas9 therapies to DMD, there are still many hurdles to overcome, such as in vivo delivery methods associated with high viral vector doses, together with safety and immunological concerns. Collectively, the results obtained in the hematological and neuromuscular fields emphasize the transformative impact of CRISPR/Cas9 for patients affected by these debilitating conditions. As each field suffers from different and specific challenges, the clinical translation of CRISPR therapies may progress differentially depending on the genetic disorder. Ongoing investigations and clinical trials will address risks and limitations of these therapies, including long-term efficacy, potential genotoxicity, and adverse immune reactions. This review provides insights into the diverse applications of CRISPR-based technologies in both preclinical and clinical settings for monogenic blood disorders and muscular dystrophy and compare advances in both fields while highlighting current trends, difficulties, and challenges to overcome.

Rare immune diseases paving the road for genome editing-based precision medicine

What a Clinician Needs to Know About Genome Editing: Status and Opportunities for Inborn Errors of Immunity

Precise Somatic Genome Editing for Treatment of Inborn Errors of Immunity.

The CRISPR-Cas System and Clinical Applications of CRISPR-Based Gene Editing in Hematology with a Focus on Inherited Germline Predisposition to Hematologic Malignancies

Recent Therapeutic Gene Editing Applications to Genetic Disorders

CRISPR-Based Gene Editing Techniques in Pediatric Neurological Disorders

Rare Opportunities: CRISPR/Cas-Based Therapy Development for Rare Genetic Diseases

Advances in CRISPR/Cas gene therapy for inborn errors of immunity

Development and application of CRISPR/Cas9 technologies in genomic editing.

The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Inherited Diseases

The Interface of Gene Editing with Regenerative Medicine

Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease

Precision in Action: The Role of Clustered Regularly Interspaced Short Palindromic Repeats/Cas in Gene Therapies

Homology-Directed-Repair-Based Genome Editing in HSPCs for the Treatment of Inborn Errors of Immunity and Blood Disorders

Prime Editing for Human Gene Therapy: Where Are We Now?

CRISPR/Cas9-mediated genome editing: from basic research to gene therapy

Challenges and progress related to gene editing in rare skin diseases

CRISPR-Based Gene Therapies: From Preclinical to Clinical Treatments

CRISPR-based strategies in infectious disease diagnosis and therapy

A comprehensive review on the current status of CRISPR based clinical trials for rare diseases

Cas9 immunity creates challenges for CRISPR gene editing therapies